Search Results - "Majewski, I."

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML by DiNardo, C.D., Tiong, I.S., Quaglieri, A., MacRaild, S., Loghavi, S., Brown, F.C., Thijssen, R., Pomilio, G., Ivey, A., Salmon, J.M., Glytsou, C., Fleming, S.A., Zhang, Q., Ma, H., Patel, K.P., Kornblau, S.M., Xu, Z., Chua, C.C., Chen, Xufeng, Blombery, P., Flensburg, C., Cummings, N., Aifantis, I., Kantarjian, H., Huang, D.C.S, Roberts, A.W., Majewski, I.J., Konopleva, M., Wei, A.H.

“…The BCL-2 inhibitor venetoclax combined with hypomethylating agents or low-dose cytarabine represents an important new therapy for older or unfit patients with…”
Get full text

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab by Loibl, S., Majewski, I., Guarneri, V., Nekljudova, V., Holmes, E., Bria, E., Denkert, C., Schem, C., Sotiriou, C., Loi, S., Untch, M., Conte, P., Bernards, R., Piccart, M., von Minckwitz, G., Baselga, J.

“…The predictive value of PIK3CA mutations in HER2 positive (HER2+) breast cancer treated with neoadjuvant anti-HER2 and chemotherapy has been reported, but the…”
Get full text

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab by Loibl, S, Majewski, I, Guarneri, V, Nekljudova, V, Holmes, E, Bria, E, Denkert, C, Schem, C, Sotiriou, C, Loi, S, Untch, M, Conte, P, Bernards, R, Piccart, M, von Minckwitz, G, Baselga, J

Get full text

Corrections to “PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab” by Loibl, S., Majewski, I., Guarneri, V., Nekljudova, V., Holmes, E., Bria, E., Denkert, C., Schem, C., Sotiriou, C., Loi, S., Untch, M., Conte, P., Bernards, R., Piccart, M., von Minckwitz, G., Baselga, J.

Get full text

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab by Loibl, S, Majewski, I, Guarneri, V, Nekljudova, V, Holmes, E, Bria, E, Denkert, C, Schem, C, Sotiriou, C, Loi, S, Untch, M, Conte, P, Bernards, R, Piccart, M, von Minckwitz, G, Baselga, J

Get full text

S140: SINGLE‐CELL MULTIOMICS ANALYSES REVEAL COMPLEX INTRA‐PATIENT HETEROGENEITY IN RELAPSED CLL FOLLOWING VENETOCLAX THERAPY by Thijssen, R., Tian, L., Flensburg, C., Anderson, M. A., Jarratt, A., Peng, H., Majewski, I., Tam, C., Seymour, J., Blombery, P., Ritchie, M., Huang, D., Roberts, A.

Get full text

PO-467 Integrative modelling to understand and predict cancer drug response by Jastrzebski, K, Thijssen, B, Majewski, I, Mulder, L, Ramshorst, M Van, Lips, E, Sonke, G, Wesseling, J, Beijersbergen, R, Wessels, L

“…IntroductionResponse to cancer therapeutics, whether in cell lines or patients, is variable and often difficult to predict. While many oncogenic drivers and…”
Get full text

Restriction Endonuclease Analysis of the Genome of Campylobacter pylori with a Rapid Extraction Method: Evidence for Considerable Genomic Variation by Goodwin, C. Stewart, Majewski, Suzanne I. H.

“…We developed a rapid extraction method to analyze the chromosomal DNA of 84 isolates of Campylobaeter pylori (formerly Campylobaeter pyloridis) from 70…”
Get full text

Correction to: PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab by Loibl, S., Majewski, I., Guarneri, V., Nekljudova, V., Holmes, E., Bria, E., Denkert, C., Schem, C., Sotiriou, C., Loi, S., Untch, M., Conte, P., Bernards, R., Piccart, M., von Minckwitz, G., Baselga, J.

Get full text

22PDEVELOPMENT OF A BRCA1-LIKE SIGNATURE IN TRIPLE NEGATIVE BREAST CANCERS WITHIN THE RATHER (RATIONAL THERAPY FOR BREAST CANCER) CONSORTIUM by Simon, I.M., Peeters, J., Severson, T., Majewski, I., Bosma, A., Caldas, C., Chin, S., Bernards, R., Linn, S.

Get full text

Development of a BRCA1-Like Signature in Triple Negative Breast Cancers Within the Rather (Rational Therapy for Breast Cancer) Consortium by Simon, I.M., Peeters, J., Severson, T., Majewski, I., Bosma, A., Caldas, C., Chin, S., Bernards, R., Linn, S.

Get full text

Abstract P6-04-02: Defining clinically relevant molecular subtypes in lobular breast cancer within the RATHER consortium by Linn, S, Majewski, I, Michaut, M, Peeters, J, Schouten, P, de Koning, L, He, B, Fan, Y, Tarrant, F, Oconnor, D, Rueda, O, Chin, S-F, Heijmans, J, Snel, M, Severson, T, Bosma, A, Mittempergher, L, Bismeijer, T, Dubois, T, Wessels, L, Simon, I, Gallagher, W, Caldas, C, Bernards, R

“…Abstract Background: The Rational Therapy for Breast Cancer (RATHER) Consortium aims to identify novel kinase targets for therapy in poor-prognosis subtypes of…”
Get full text

Possibilities of evaluating the stability of total lower dentures by means of modern radiodiagnostic methods by Rother, U, Schubert, H, von Majewski, I

Get more information

Unusual Course of Acne Conglobata as a Skin Manifestation due to Bilateral Luteoma of Pregnancy by Katarzyna Smolarczyk, Tomasz Pniewski, Roman Smolarczyk, Alicja Adaszewska, Slawomir Majewski

Get full text

Treatment Outcome and Prognostic Factors for Malignant Skin Melanoma Treated with Radical Surgery by Majewski, Wojciech, Stanienda, Karolina, Wicherska, Katarzyna, Ulczok, Rafal, Wydmanski, Jerzy

“…Aim: To assess the treatment outcome in patients with malignant skin melanoma and prognostic factors for distant metastases (DM), disease-free survival (DFS)…”
Get full text